News - NRG1 fusion - LARVOL VERI

Structure, mechanism and clinical relevance of NRG1 fusions in cancer. (PubMed, J Biomed Sci)

This gives a better understanding of the biology of NRG1 fusions, and will help in the development of new therapeutic approaches. Our methodology described in this review can also be used for the study of other genes with disease-related fusions.

6 days ago

Review • Journal

NRG1 (Neuregulin 1)

NRG1 fusion

Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases. (PubMed, Virchows Arch)

KRAS G12C-mutated NSCLC is clinically aggressive and frequently shows solid growth with rhabdoid, plasmacytoid, or SCC-like morphology, which may lead to misclassification and missed genetic testing. Immunohistochemistry and molecular profiling are essential for accurate classification and enabling targeted therapy.

7 days ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • STK11 (Serine/threonine kinase 11) • NRG1 (Neuregulin 1) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • NKX2-1 (NK2 Homeobox 1) • GNAS (GNAS Complex Locus) • TP63 (Tumor protein 63) • NAPSA (Napsin A Aspartic Peptidase)

PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • STK11 mutation • FGFR2 mutation • MET mutation • NRG1 fusion • KRAS G12

22d

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions. (PubMed, Vet Comp Oncol)

These disruptions could impair tumour-suppressive pathways, presenting additional therapeutic targets. This research emphasises the broader relevance of fusion-driven mechanisms in cPAC tumorigenesis, advancing the understanding of both canine and human lung cancers for clinical and comparative studies.

22 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1) • SDC4 (Syndecan 4)

HER-2 overexpression • NRG1 fusion

29d

Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard-of-Care and Emerging Therapeutic Strategies. (PubMed, J Gastroenterol Hepatol)

Emerging immunotherapies targeting Claudin18.2 and CXCR4 offer hope to overcome tumor resistance. Together, these strategies underscore the promise of molecular stratification, synthetic lethality, and novel targets to improve pancreatic cancer survival.

29 days ago

Review • Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • HRD (Homologous Recombination Deficiency) • CLDN18 (Claudin 18) • NRG1 (Neuregulin 1) • MTAP (Methylthioadenosine Phosphorylase) • CXCR4 (Chemokine (C-X-C motif) receptor 4)

HRD • KRAS wild-type • MTAP deletion • RAS wild-type • NRG1 fusion

What for patients with NRG1 fusions? Looking into Pandora's box. (PubMed, Crit Rev Oncol Hematol)

Multiple strategies are employed to achieve ever-increasing efficacy of the newly proposed therapies, including combination therapies with other targeted approaches, small compounds, and monoclonal antibodies. This narrative review summarizes the available data on the spectrum of all available drugs targeting NRG1/HER deregulation in cancers with NRG1 fusions, their chemistry, pharmacodynamics, pharmacokinetics, and metabolism, as well as the clinical efficacy in NRG1-positive patients.

1 month ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1) • ERBB4 (erb-b2 receptor tyrosine kinase 4)

NRG1 fusion

Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort. (PubMed, Lung Cancer)

NRG1 fusions were identified in 0.8% of NSCLC, exceeding historical estimates and underscoring the importance of RNA-based NGS for fusion detection. The clinical and molecular profile mirrored prior reports, with predominant female patients, IMA histology, PD-L1 negativity, and low TMB. Outcomes were poor in metastatic patients lacking access to targeted therapy, supporting the need for broader implementation of RNA sequencing and access to anti-HER3 agents.

1 month ago

Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRG1 (Neuregulin 1) • CD74 (CD74 Molecule) • SLC3A2 (Solute Carrier Family 3 Member 2) • SDC4 (Syndecan 4) • WRN (WRN RecQ Like Helicase) • VAMP2 (Vesicle Associated Membrane Protein 2)

KRAS mutation • PD-L1 negative • TMB-L • NRG1 fusion

Analysis of clinical and genomic features in a Chinese cohort with NRG1 variations: a retrospective study. (PubMed, Transl Lung Cancer Res)

This study revealed the distinct clinicogenomic landscapes of NRG1 fusions and SNVs in NSCLC. These findings emphasize the important role of molecular profiling for precision diagnosis and individualized treatment of NSCLC.

1 month ago

Retrospective data • Journal • Tumor mutational burden • IO biomarker

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • NRG1 (Neuregulin 1) • CD74 (CD74 Molecule) • KMT2A (Lysine Methyltransferase 2A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

KRAS mutation • EGFR mutation • TMB-H • ARID1A mutation • NRG1 fusion

2ms

ASPiRATION-2 Liquid: An observational cohort study to assess the impact of longitudinal molecular profiling using circulating tumour DNA (ctDNA) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) after failure of genomically targeted therapy. (ACTRN12626000225314)

P=N/A, N=500, Not yet recruiting, The University of Sydney

2 months ago

New trial • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRAF mutation • MET exon 14 mutation • RET mutation • ROS1 fusion • NRG1 fusion

FoundationOne® CDx • TruSight Oncology 500 Assay

2ms

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (clinicaltrials.gov)

P3, N=94, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NRG1 (Neuregulin 1)

BRAF V600E • MSI-H/dMMR • PALB2 mutation • KRAS wild-type • BRAF wild-type • RAS wild-type • ROS1 fusion • NRG1 fusion

gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical

3ms

NRG1 fusions：the potential targeted treatment in non-small cell lung cancer(NSCLC). (PubMed, Crit Rev Oncol Hematol)

Critical challenges persist, such as intrinsic resistance mediated by the heterogeneity of NRG1 fusion isoforms and compensatory activation of the epidermal growth factor receptor (EGFR) pathway. This comprehensive analysis underscores the unmet need for novel therapeutics and provides a framework for optimizing precision oncology strategies in this molecularly defined NSCLC subset, highlighting the necessity for standardized diagnostic protocols and globally collaborative clinical trials.

3 months ago

Review • Journal

ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)

NRG1 fusion

3ms

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=100, Recruiting, Cogent Biosciences, Inc.

3 months ago

New P1 trial

HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1)

HER-2 overexpression • HER-2 mutation • NRG1 fusion